Fidelity Investments’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Fidelity Investments’s Portfolio GEVA Stock Details GEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-5,543,741	Closed	-$541M	–	2882
2015 Q1	$541M	Buy	5,543,741 +959,650	+21%	+$102M	0.07%	323
2014 Q4	$425M	Buy	4,584,091 +701,050	+18%	+$55.3M	0.06%	382
2014 Q3	$267M	Buy	3,883,041 +272,440	+8%	+$19.5M	0.04%	522
2014 Q2	$378M	Buy	3,610,601 +923,637	+34%	+$78.6M	0.05%	411
2014 Q1	$223M	Sell	2,686,964 -350,255	-12%	-$32.4M	0.03%	605
2013 Q4	$197M	Sell	3,037,219 -147,409	-5%	-$8.75M	0.03%	640
2013 Q3	$202M	Buy	3,184,628 +378,541	+13%	+$18.6M	0.03%	605
2013 Q2	$118M	Buy	+2,806,087	New	+$128M	0.02%	837

Fidelity Investments's GEVA Position: Q2 2015 in Review

Fidelity Investments sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 5,543,741 shares — an estimated $541M sold.

Fidelity Investments first reported a position in GEVA in Q2 2013 and held it in 8 quarters. The position peaked at $541M in Q1 2015. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

Fidelity Investments reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
Fidelity Investments sold 5,543,741 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $541M.
Fidelity Investments first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 8 quarters.
Fidelity Investments's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $541M in Q1 2015.
0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on Fidelity Investments's 13F filing for Q2 2015, filed 13 Aug 2015.